Key result
Hydroxychloroquine use is linked to ~42% lower risk of neuropsychiatric damage in SLE.
Cohort (n=632)
Answers are grounded in this paper and cite their sources.
The aims of this study were to examine the predictors of time to neuropsychiatric (NP) damage and its impact on mortality in 632 systemic lupus erythematosus African-American, Hispanic and Caucasian LUpus in MInorities: NAture versus Nurture (LUMINA) patients, age >or= 16 years and disease duration <or=5 years at baseline (T0). Time-to-NP damage and its impact on mortality were examined by Cox proportional hazards regressions. A total of 185 (29.3%) patients developed NP damage over a mean (SD) disease duration of 5.6 (3.7) years. After adjusting for NP manifestations present, older age [Hazard ratio (HR) = 1.02; 95% Confidence interval (CI) 1.00-1.04], Caucasian ethnicity (HR = 1.87; 95% CI, 1.22-2.87), disease activity over the disease course (HR = 1.16; 95% CI, 1.12-1.21), diabetes (HR = 3.47; 95% CI, 1.44-8.38) and abnormal illness-related behaviours (HR = 1.05; 95% CI, 1.02-1.08) were associated with a shorter time-to-NP damage. Photosensitivity (HR = 0.65; 95% CI, 0.44-0.95), anaemia (HR = 0.56; 95% CI, 0.31-0.98), Raynaud's phenomenon (HR = 0.49; 95% CI, 0.34-0.72), a medium dose of prednisone (HR = 0.56; 95% CI, 0.35-0.92) and hydroxychloroquine use (HR = 0.58; 95% CI, 0.36-0.93) were associated with a longer time. NP damage did not contribute to mortality. Older age, Caucasian ethnicity, disease activity and abnormal illness-related behaviours are associated with a shorter time-to-NP damage; hydroxychloroquine and a medium dose of prednisone with a longer time.
No takes yet. Share an insight, caveat, or question.
González et al. (2009) conducted a cohort in Systemic lupus erythematosus (SLE) (n=632). Clinical and demographic predictors (e.g., hydroxychloroquine use, prednisone, disease activity, age, ethnicity) vs. Absence of respective predictors / reference categories was evaluated on Time to neuropsychiatric (NP) damage occurrence (HR 0.58, 95% CI 0.36-0.93). Hydroxychloroquine and medium-dose prednisone delayed neuropsychiatric damage in SLE, whereas disease activity and diabetes accelerated it.
Synapse has enriched 10 related papers. Consider them for comparative context: